December 7, 2018 05:25 AM ESTUpdated April 22, 12:12 PM
R&D

As­traZeneca's prized Imfinzi/treme­li­mum­ab com­bo fails again — this time in head and neck can­cer

ENDPOINTS

As­traZeneca’s big bet on a com­bi­na­tion of its check­point in­hibitor Imfinzi and in-house CT­LA-4 drug has proved ex­ceed­ing­ly cost­ly. The British drug­mak­er con­ced­ed on Fri­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times